Contact this trialFirst, we need to learn more about you.
Small Molecule Inhibitor
Tepotinib +/- Osimertinib for Brain Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial will assess the safety and efficacy of tepotinib in patients with brain tumors and MET alterations. The study will be conducted in two parts, with the first part exploring different doses of the drug and the second part expanding upon the most promising dose from the first part.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.